Neuren receives $1 million R&D Tax Incentive
Filed with ASX · · 1 page · English
Neuren Pharmaceuticals Limited on 6ix
In the deck
Earlier from Neuren Pharmaceuticals
- Trofinetide significant clinical benefit in Rett syndrome
- Neuren completes Phase 2 trial in pediatric Rett syndrome
- Notice of special meeting of shareholders
- Neuren completes enrolment in Rett syndrome Phase 2 trial
- Neuren receives $0.9m from exercise of last expiring options
Later from Neuren Pharmaceuticals
- Response to Appendix 4C Query
- Notice of Annual General Meeting/Proxy Form
- Neuren announces grant of two new patents to 2032
- Investor presentation, 2 June 2017
- Trading Halt
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals